FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mitchell Shawnte
2. Issuer Name and Ticker or Trading Symbol

Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP, GC and Corporate Affairs
(Last)          (First)          (Middle)

2401 4TH AVENUE, SUITE 1050
3. Date of Earliest Transaction (MM/DD/YYYY)

2/18/2020
(Street)

SEATTLE, WA 98121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $0.498 2/18/2020  A   134800     (1)2/17/2030 Common Stock 134800 $0 134800 D  

Explanation of Responses:
(1) The option vests in three approximately equal annual installments beginning on February 17, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Mitchell Shawnte
2401 4TH AVENUE
SUITE 1050
SEATTLE, WA 98121


SVP, GC and Corporate Affairs

Signatures
/s/ Carl A. Valenstein, attorney-in-fact3/19/2020
**Signature of Reporting PersonDate

Aptevo Therapeutics (PK) (USOTC:APVTW)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Aptevo Therapeutics (PK) 차트를 더 보려면 여기를 클릭.
Aptevo Therapeutics (PK) (USOTC:APVTW)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Aptevo Therapeutics (PK) 차트를 더 보려면 여기를 클릭.